BioSpace News Archive

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality.

Oligomerix, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.”

Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.

Lipocine Inc. announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners.

Kira Pharmaceuticals announced that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at 9:00 AM PT on Thursday, January 12, 2023.

OnQuality Pharmaceuticals (“OnQuality”) today announced that regulatory authorities in China and India have approved Part 2 of the NOVA-II Phase 2 clinical trial, evaluating OQL011, a topical ointment for the management of Hand-Foot Skin Reaction (HFSR) in cancer patients receiving vascular endothelial growth factor receptor (VEGFR) inhibitor(s) (VEGFRi) as part of their anti-cancer treatment.

Conformal Medical, Inc. announced the publication of the peer-reviewed article, “Foam-based Left Atrial Appendage Closure Device: Evaluation in a Chronic Canine Model,” in the Journal of the Society for Cardiovascular Angiography and Interventions.

Seal Rock Therapeutics, Inc. will present at Biotech Showcase 2023, taking place January 9-11, 2023 in San Francisco .

AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing.